Tag Archives: Dual Agonist

Boehringer Ingelheim Advances Dual Agonist Survodutide to Phase III Trials, Demonstrating Significant Weight Loss in Phase II Study

(IN BRIEF) Pharmaceutical company Boehringer Ingelheim has declared its intention to move forward with survodutide, a dual agonist targeting the glucagon/GLP-1 receptors, into three Phase III clinical trials for individuals suffering from overweight or obesity. This decision stems from promising … Read the full press release